The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict DexCom's revenues will expand 40.6% and EPS will remain in the red.
The average estimate for revenue is $28.3 million. On the bottom line, the average EPS estimate is -$0.17.
Last quarter, DexCom logged revenue of $33.3 million. GAAP reported sales were 48% higher than the prior-year quarter's $22.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at -$0.15. GAAP EPS were -$0.12 for Q4 versus -$0.18 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 51.0%, 310 basis points better than the prior-year quarter. Operating margin was -27.9%, much better than the prior-year quarter. Net margin was -25.5%, much better than the prior-year quarter.
The full year's average estimate for revenue is $129.4 million. The average EPS estimate is -$0.54.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 79 members out of 176 rating the stock outperform, and 97 members rating it underperform. Among 61 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 23 give DexCom a green thumbs-up, and 38 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DexCom is outperform, with an average price target of $15.31.
Is DexCom the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add DexCom to My Watchlist.